Brief: Medicus Pharma Provides Update On SKNJCT-003 Phase 2 Clinical Study
14/02/2025 12:33
Feb 14 (Reuters) - Medicus Pharma MDCX.V :
* MEDICUS PHARMA PROVIDES UPDATE ON SKNJCT-003 PHASE 2
CLINICAL
STUDY FOR THE TREATMENT OF NODULAR BASAL CELL CARCINOMA (BCC)
* MEDICUS PHARMA LTD - TO COMPLETE INTERIM DATA ANALYSIS BY
END OF
Q1 2025
* MEDICUS PHARMA LTD - TO SEEK TYPE C MEETING WITH FDA IN Q2
2025
Source text: ID:nGNX8vPNlH
Further company coverage: MDCX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicus Pharma
See all newsBrief: Medicus Pharma Provides Update On SKNJCT-003 Phase 2 Clinical Study
Brief: Medicus Pharma Enters Into Standby Equity Purchase Agreement
Brief: Medicus Pharma Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Brief: FSD Pharma Wins Final Judgment To Confirm Arbitration Award Of $3.06 Mln Plus Interest Entered Against Raza Bokhari
Brief: Medicus Pharma Ltd Files For U.S. IPO - SEC Filing